{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=10", "query": { "condition": "Gastroesophageal Junction Adenocarcinoma", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 342, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:45:36.863Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Invasive Breast Lobular Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 138, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT06356311", "title": "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Trifluridine-Tipiracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Rescue medications", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-05-03", "completion_date": "2027-05-06", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06356311" }, { "nct_id": "NCT01170663", "title": "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Ramucirumab (IMC-1211B) DP", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 665, "start_date": "2010-12", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 13, "location_summary": "Burbank, California • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170663" }, { "nct_id": "NCT00982592", "title": "Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Adenocarcinoma of the Stomach", "Recurrent Gastric Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "vismodegib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2009-09", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-01-25", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 30, "location_summary": "Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Effingham", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00982592" }, { "nct_id": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2019-08-29", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 11, "location_summary": "Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929666" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2021-08-27", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT00757172", "title": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 21, "location_summary": "Savannah, Georgia • Chicago, Illinois • Evanston, Illinois + 15 more", "locations": [ { "city": "Savannah", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00757172" }, { "nct_id": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Cancer", "Triple Negative Breast Cancer (TNBC)", "Urothelial Carcinoma Bladder", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Gastric Cancer", "Cancer", "Solid Tumors (Phase 1)" ], "interventions": [ { "name": "RNDO-564", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rondo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2025-11-17", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218003" }, { "nct_id": "NCT06764875", "title": "A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2025-03-01", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 58, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764875" }, { "nct_id": "NCT00711412", "title": "Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Induction Therapy - Capecitabine", "type": "DRUG" }, { "name": "Induction Therapy - Oxaliplatin", "type": "DRUG" }, { "name": "Combination Therapy - Capecitabine", "type": "DRUG" }, { "name": "Combination Therapy - Oxaliplatin", "type": "DRUG" }, { "name": "Combination Therapy - Radiation", "type": "RADIATION" }, { "name": "Evaluation for response and surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 44, "start_date": "2006-05-31", "completion_date": "2013-01-30", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-13T23:45:36.863Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711412" } ] }